New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
04:55 EDTEBIO, EBIO, EBIO, EBIO, SURG, SURG, SURG, SURG, DNA, DNA, DNA, DNA, XOMA, XOMA, XOMA, XOMA, SQNM, SQNM, SQNM, SQNM, REGN, REGN, REGN, REGN, MRK, MRK, MRK, MRK, CAJ, CAJ, CAJ, CAJ, AGN, AGN, AGN, AGN, AGTC, AGTC, AGTC, AGTC, VRX, VRX, VRX, VRXAssociation for Research in Vision & Ophthalmology holds annual meeting
2014 Annual Meeting of ARVO is being held in Orlando, Florida on May 4-8.
News For EBIO;AGTC;AGN;CAJ;MRK;REGN;SQNM;XOMA;DNA;SURG;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 20, 2014
12:23 EDTAGN, VRXAllergan holder Paulson encourages deal with Shire, Reuters says
Subscribe for More Information
09:25 EDTVRX, AGNValeant says talks to Ackman 'frequently'
Subscribe for More Information
09:08 EDTAGN, VRXValeant says not planning to walk away from Allergan deal before Dec. 18
Subscribe for More Information
08:58 EDTAGN, VRXValeant says still willing to improve bid for Allergan
Valeant (VRX) said would raise Allergan (AGN) bid "when time is right." Says hopes Allergan shareholders see that Valeant's operating model does work and will continue to work. Says Valeant (VRX), Allergan have "unique" business overlap. Says company "should" own Allergan. Says interests with Pershing, Ackman "aligned" on Allergan.
08:37 EDTAGN, VRXValeant says 'completely focused' on Allergan acquisition
Subscribe for More Information
08:06 EDTMRKMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:34 EDTMRKAdvaxis names Mauro Chief Medical Officer
Advaxis (ADXS) announced that it has appointed David Mauro, as executive vice president, Chief Medical Officer Mauro most recently served as executive director, section head oncology clinical development at Merck (MRK). In connection with his appointment, Mauro received a one-time inducement award of 165K restricted shares, of which 55K are fully vested and as of the grant date. The remaining shares vest annually over a two-year period.
07:34 EDTVRX, AGNValeant says remains focused on completing Allergan transaction
Subscribe for More Information
07:32 EDTVRXValeant narrows FY14 revenue view to $8.1B-$8.3B from $8B-$8.3B
Subscribe for More Information
07:30 EDTAGN, VRXValeant CEO says 'can bid more than anyone' in financially sound Allergan deal
Pearson says "we cannot stop" another company from making a bid that does not make economic sense, but he believes Valeant (VRX) can "bid more than anyone" for Allergan (AGN) in a deal that makes financial sense. Pearson says he has met with doctor groups and that 95% of those he's spoken with support Valeant's bid for Allergan. Valeant CEO J. Michael Pearson spoke on CNBC.
07:28 EDTVRXValeant raises FY14 cash EPS to $8.22-8.32 from $7.90-$8.10
Subscribe for More Information
07:19 EDTMRKIBC Life Sciences to hold a conference
Subscribe for More Information
07:16 EDTDNA, REGN, SURG, AGN, CAJ, XOMAAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
07:11 EDTMRKAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTREGNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTVRXValeant raises FY15 outlook cash EPS $10.00 from $9.90
Subscribe for More Information
07:05 EDTVRXValeant raises Q4 cash EPS $2.45-$2.55 from $2.35-$2.45
Subscribe for More Information
07:03 EDTVRXValeant reports Q3 cash EPS $2.11, Q3 GAAP EPS 81c
Reports Q3 revenue revenue $2.1B; Reports Q3 total same store sales organic growth 19%. Bausch + Lomb organic growth was 12%. Q3 GAAP Operating Cash Flow $619 million, an increase of 207%; Adjusted Operating Cash Flow $771 million, an increase of 89%
07:02 EDTREGNRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
06:28 EDTAGNAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use